Oligonucleotides Archives

Supporting Discovery of mRNA Drugs

Unlike conventional protein-targeted therapies, which often provide only transient effects, nucleic acid therapeutics have the potential for long-lasting effects and...

Advanced Conjugate Delivery Systems for Oligonucleotides

Oligonucleotide therapeutics represent a transformative treatment modality with demonstrated potential across metabolic disorders, CNS diseases, muscular dystrophies, and a broad...

Antibody-Targeted Precision Medicines

Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...

Evaluations of Targeted Delivery Systems for RNA Therapeutics

RNA therapeutics can target specific mRNAs with high specificity, making them advantageous for treating genetic diseases caused by known mutations....

End-to-End CRDMO Platform for Oligonucleotide Drugs

Since the approval of the first siRNA drug in 2018, oligonucleotide therapeutics have rapidly emerged as a promising drug modality. ...

Integrated Platform Supporting ASO Drug Discovery

Antisense oligonucleotides (ASOs) are single-stranded, synthetic chains of DNA or RNA designed to bind to specific RNA sequences through complementary...